Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 292 results found. Search for [ Aurobindo Pharma ]

Results 80 to 100 of 292
BusinessToday.In
April 2, 2020
Stocks to watch today on April 3: Kilpest India, Cipla, TVS Motor, Aurobindo Pharma, JB Chemicals, AIMCO Pesticides among others are the top stocks to watch out for in Friday's trading session


Ajita Shashidhar and E Kumar Sharma
New Delhi, April 1, 2020
FMCG, online retail, telecom and pharma seem to be the obvious gainers of the Covid-19 pandemic


BusinessToday.In
March 17, 2020
Share Market LIVE Updates: Where Sensex ended 810 points lower to 30,579, Nifty closed 229 points to trade at 8,968 mark.


Rupa Burman Roy
March 5, 2020
Barring shares of Piramal Enterprises that fell around 0.3%, all the 9 other healthcare shares were trading higher on Nifty Pharma, that was up 0.78% at 8,200.


BusinessToday.In
March 5, 2020
Share Market Update: BSE 30-share S&P Sensex closed 61 points higher at 38,470 and Nifty50 ended 18 points higher at 11,269


Rupa Burman Roy
March 4, 2020
On both the bourses, BSE and NSE, the pharma sector outperformed the broader market, which fell amid rising uncertainty among investors.  In the month of March, the healthcare sector on BSE has overall gained 473 points or 3.5%.


BusinessToday.In
February 24, 2020
price of Aurobindo Pharma fell up to 18% to Rs 491.90 against previous close of Rs 599.55 on BSE


BusinessToday.In
February 24, 2020
Share Market Update: BSE 30-share S&P Sensex ended 806 points lower at 40,363 and NSE 50-share index Nifty50 closed 251 points lower at 11,829


Rupa Burman Roy
February 19, 2020
Following the update, share price of Aurobindo Pharma formed a gap up chart pattern with the opening bell, rising 10%. Later, the stock touched an intraday high of Rs 594, rising 18.75% on BSE as against the previous closing value of Rs 500.20 on BSE.


BusinessToday.In
February 19, 2020
Share Market Update :BSE 30-share S&P Sensex ended 428 points higher at 41,323 and NSE 50-share index Nifty50 closed 137 points higher at 12,130


BusinessToday.In
February 6, 2020
Avenue Supermarts shares on Thursday gained 4.95% to the intraday high as well as its new-52 week and all-time high of Rs 2,360.75 today, as against its previous close of Rs 2,249.30.


BusinessToday.In
February 6, 2020
Drug firm Cadila Healthcare reported a 249% rise in Q3 net profit at Rs 373.9 crore compared to Rs 82.90 crore profit in Q2 of current fiscal


BusinessToday.In
February 6, 2020
Share Market Update: BSE 30-share S&P Sensex ended 144 points higher at 41,313 and NSE 50-share index Nifty50 closed 44 points higher at 12,133.


BusinessToday.In
February 5, 2020
Stocks to watch today on February 6: Sun Pharma, Adani Power, Eicher Motors, RITES, Hero MotoCorp, Aurobindo Pharma among others are the top stocks to watch out for in Thursday's trading session


E Kumar Sharma
New Delhi, January 1, 2020
Biosimilars are a different ball game -- more complex and more expensive, essentially because biotech drugs, by their very nature, require understanding of living organisms


PB Jayakumar
December 30, 2019
The USFDA's Office of Manufacturing Quality (OMQ) at the Centre for Drug Evaluation Research (CDER) evaluates compliance with cGMP for drugs based on inspection reports and evidence gathered by USFDA investigators


Anup Jayaram
New Delhi, December 17, 2019
Oracle formally opened up its Oracle Cloud Applications through its \"Gen 2\" Cloud region in Mumbai, which became operational in December


BusinessToday.In
November 29, 2019
Aurobindo Pharma share price gained 2.67% to Rs 462.2 compared to the previous close of Rs 450.20 on BSE


BusinessToday.In
New Delhi, November 28, 2019
HDFC Bank shares will be in focus after the lender said it has constituted a six-member search committee to replace Aditya Puri as managing director and chief executive officer of the bank, whose tenure ends on October 26, 2020


E Kumar Sharma
New Delhi, November 25, 2019
A number of biologics with huge markets are going off-patent in the US. Do Indian pharmaceutical companies have it in them to play this high-cost, high-risk game of launching biosimilars?


PAGES 5 OF 15  12345